| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |